

PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for form 1449/PTO 10/696,261 **Application Number** INFORMATION DISCLOSURE October 29, 2003 Filing Date STATEMENT BY APPLICANT Wilson et al First Named Inventor 1635 Group Art Unit Brian A. Whiteman (Use as many sheets as necessary) **Examiner Name** GNV31CUSA/K1774DIV2 Attorney Docket Number of Sheet

		NONPATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
þν	LLL	ZHI ET AL, Increased Antigen-Specific Humoral Response by Adenoviral Vector Prime and Adeno-Associated Viral Vector Boost, Abstract 569, 7 th Annual Meeting of the American Society of Gene Therapy [June 2-6, 2004] Minneapolis, Minnesota, (e-publ. May 2, 2004)	
<i>p</i> ~	MMM	BOYER ET AL, Anti-SARS Humoral And Cellylar Immunity Evoked by Adenovirus Vector Expressing Spike Glycoprotein from SARS Coronavirus, Abstract 558, 7 th Annual Meeting of the American Society of Gene Therapy [June 2-6, 2004] Minneapolis, Minnesota, (e-publ. May 2, 2004)	
<u> </u>			
• .			

- In		Date	11 Con rei	
Examiner		Date	1 417 / 11/11	\
Signature 1) Aug 1	•	Considered	שוטנווון	
Signature 17 Aug.				

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation in not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chlef Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08B (04-03)
Approved for use through 4/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it

contains a v	contains a valid OMB control number.			Complete if Known			
Substitute	for form	1449/PTO		Application Number	10/696,261		
	TNFC	ORMA1	TION	Filing Date	October 29, 2003		
		CLOS		First Named Inventor	Wilson et al		
	STATEMENT BY		Group Art Unit	1635			
	APPLICANT (Use as many sheets as necessary)		Examiner Name	Brian A. Whiteman			
Sheet	use as m.	of	2	Attorney Docket Number	GNV31CUSA/ UPN-K1774DIV2		

	Cite	Document Number	Publication Date		Pages, Columns, Lines, Where Relevant Passages or Relevant
	No.1	Number-Kind Code ^{2(ifknown)}	MM-DD-YYYY	Applicant of Cited Document	Figures Appear
B.L	FFF	US-2004-0057932 A	1 03-25-2004	Wilson et al	
'}	GGG	US-2004-0057933 A	1 03-25-2004	Wilson et al	
N.	ннн	US-6,759,237 B	1 07-06-2004	Wilson et al	

		FOREIGN PA	ATENT DOCUMENTS			···
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т6
						_
					<u> </u>	_

Examiner	Considered (1) (1) (1)
* EXAMINER: Initial If reference considered, whether or not of	citation is in conformance with MPEP 609. Draw line
	ude copy of this form with next communication to

through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450.

Approved for use through 4/30/2003.

OMB 0651-0031

U.S. Patent and Trademark Office;

U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it valid OMB control number.

contains a valid OMB control number. Substitute for form 1449/PTO			·	Complete if Known			
		D14 A	TTON	Application Number	10/696,261		
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	October 29, 2003			
			First Named Inventor	James M. Wilson			
			Group Art Unit	1635			
(Use as many sheets as necessary)		Examiner Name	Brian A. Whiteman				
Sheet	Sheet 2 of 2		2	Attorney Docket Number	GNV31CUSA/ UPN-K1774DIV2		

Disseminated in Human Tissues, Journal of Virology, Vol. 78, No. 12, pp. 6381-6388, (June 2004) JJJ GAO ET AL, Erythropoietin Gene Therapy Leads to Autoimmune Anemia in Macaques, Blood, Vol. 103, No. 9, (May 1, 2004) KKK RICK ET AL, Congenital Bleeding Disorders, American Society	Cite No.¹	(when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), columeousse number(s), publisher, city and/or country where published	T ²
Autoimmune Anemia in Macaques, Blood, Vol. 103, No. 9, (May 1, 2004) KKK RICK ET AL, Congenital Bleeding Disorders, American Society	Ш	GAO ET AL, Clades of Adeno-Associated viruses are widely Disseminated in Human Tissues, Journal of Virology, Vol. 78, No. 12, pp. 6381-6388, (June 2004)	
KKK RICK ET AL, Congenital Bleeding Disorders, American Society of Hematology, pp. 559-574, (2003)	111	GAO ET AL, Erythropoietin Gene Therapy Leads to Autoimmune Anemia in Macaques, Blood, Vol. 103, No. 9, (May 1, 2004)	
Of Hermanic Byyer	KKK	RICK ET AL, Congenital Bleeding Disorders, American Society of Hematology, pp. 559-574, (2003)	-
		III	III GAO ET AL, Clades of Adeno-Associated viruses are widely Disseminated in Human Tissues, Journal of Virology, Vol. 78, No. 12, pp. 6381-6388, (June 2004) JJJ GAO ET AL, Erythropoietin Gene Therapy Leads to Autoimmune Anemia in Macaques, Blood, Vol. 103, No. 9, (May 1, 2004) KKK RICK ET AL, Congenital Bleeding Disorders, American Society

Examiner Signature * EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is language Translation or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450.	the state of the s			
Department of Commerce Washington, DC 20231, DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDITION	* EXAMINER: Initial if reference considered, whether or not citation through citation if not in conformance and not considered. Include applicant. Applicant's unique citation designation number (optional language Translation is attached. This collection of information is refequired to obtain or retain a benefit by the public which is to file Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this concluding gathering, preparing, and submitting the completed application of the individual case. Any comments on the amount of time your property of the confidence of the property of the confidence of the property	Considered Ion is in conformance copy of this form with all. Applicant is to play and by 37 CFR 1.9 and by the USPTO to ollection is estimated cation form to the USPTO to provide the cation form to the USPTO to play a second to pl	place a check mark here if Englis of and 1.98. The information is process) an application. I to take 2 hours to complete, opto. Time will vary depending this form and/or suggestions for a compark Office, U.S.	
	required to obtain or retain a benefit by the public which is to file (confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this concluding gathering, preparing, and submitting the completed application the individual case. Any comments on the amount of time your reducing this burden, should be sent to the Chief Information Office Comments of Com	and by the USFIO do ollection is estimated cation form to the US ou require to complete ser, U.S. Patent and T FEES OR COMPLETE	to take 2 hours to complete, SPTO. Time will vary depending e this form and/or suggestions for frademark Office, U.S.	



PTO/SB/08B (04-03)

Approved for use through 4/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO 10/696,261 **Application Number** October 29, 2003 **INFORMATION** Filing Date James M. Wilson **DISCLOSURE** First Named Inventor STATEMENT BY 1635 Group Art Unit **APPLICANT** Brian A. Whiteman **Examiner Name** (Use as many sheets as necessary) GNV31CUSA/ Attorney Docket 1 of 8 Sheet UPN-K1774DIV2 Number

		U.S	. PATENT DOCUMEN	rts	
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant Passages
Initials*	No.1	Number-Kind Code ^{2(i) known}	MM-DD-YYYY	Cited Document	or Relevant Figures Appear
1.	Α	US-6,387,368 B1	05-14-2002	Wilson et al	
	В	US-6,274,354 B1	08-14-2001	Wilson et al	
	С	US-6,482,634 B1	11-19-2002	Wilson et al	
	D	US-6,475,769 B1	11-05-2002	Wilson et al	
	E	US-6,365,394 B1	04-02-2002	Gao et al	
<u>n~</u>	F	US-6,399,385 B1	06-04-2002	Croyle et al	

		FOREIGN	PAT	ENT DOCUMENTS			
_		Foreign Patent Document		D. hillanda - Daha	Name of Patentee or	Pages, Columns, Lines, Where Relevant	T6
Examiner Initials*	Cite No. ¹	Country Code ³ - Number ⁴ -Kind Code ⁵ (If known)		Publication Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	
PY	G	PCT WO03/093440 A	12	11-13-2003	University of Florida		
	H	PCT WO03/092598 A	12	11-13-2003	University of Florida		
D~	I	PCT WO98/11244 A	12	03-19-1998	J. Chiorini		

Examiner Signature	Date Considered	_ <u>I</u> 1	12010	(
			11250 500	January Han

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450.



PTO/SB/08B (04-03)
Approved for use through 4/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it

contains a valid OMB control number Complete if Known Substitute for form 1449/PTO 10/696,261 **Application Number INFORMATION** October 29, 2003 Filing Date James M. Wilson **DISCLOSURE** First Named Inventor STATEMENT BY 1635 **Group Art Unit APPLICANT** Brian A. Whiteman **Examiner Name** (Use as many sheets as necessary) GNV31CUSA/ Attorney Docket 2 Sheet of 8 **UPN-K1774DIV2** Number

		U.S	. PATENT DOCUMEN	ITS	
Examiner Initials*	Cite	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant Passages
	No.1	Number-Kini Code ²⁽⁽¹⁾	MM-DD-YYYY	Cited Document	or Relevant Figures Appear
BN	J	US-5,871,982 B1	02-16-1999	J. Wilson	
	K	US-6,258,595 B1	07-10-2001	G. Gao	
	L	US-6,274,354 B1	08-14-2001	J. Wilson	
DV	M	US-6,251,677 B1	06-26-2001	J. Wilson	

		Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines, Where	Τé
	Cite No. ¹	Country Code ³ - Number ⁴ -Kind Code ⁵ (If known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
BY	N	PCT WO96/13598 A2	05-09-1996	J. Wilson		
	0	PCT WO98/10088 A1	03-12-1998	J. Wilson		
	P	PCT WO98/10086 A1	03-12-1998	J. Wilson		
1	Q	PCT WO99/15677 A1	04-01-1999	J. Wilson		
1	R	PCT WO99/14354 A1	03-25-1999	J. Wilson		
1	S	PCT WO99/15685 A1	04-01-1999	J. Wilson		
	T	PCT WO99/47691 A1	09-23-1999	G. Gao		
	Ū	PCT WO00/55342 A1	09/21/2000	G. Gao		
<u>B</u> ,	V	PCT WO00/75353 A1	12-14-2000	W. Xiao		

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents the Indication of the content of t

www.uspto.gov or MPEP 901.04. *Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3).
*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450



PTO/SB/08B (04-03)
Approved for use through 4/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office;
U.S. DEPARTMENT OF COMMERCE
required to respond to a selection

Under the Paperwork Reduction acc of 1995, no persons are required to respond to a collection of information unless it

			Со	mplete if Known	
Substitute for form 1449/PTO				Application Number	10/696,261
	INFO	RMA'	TION	Filing Date	October 29, 2003
	DISCLOSURE			First Named Inventor	James M. Wilson
	STATE	MEN	IT BY	Group Art Unit	1635
C	APP		NT s as necessary)	Examiner Name	Brian A. Whiteman
Sheet	3	of	8	Attorney Docket Number	GNV31CUSA/ UPN-K1774DIV2

	U.S. PATENT DOCUMENTS										
Examiner	Cite	Document Number	Publication Date	Name of Patentee	Pages, Columns, Lines, Where Relevant Passages						
Initials*	No.1	Number-Kind Code ²⁽⁽¹⁵⁰⁰⁴⁰⁾ MM-DD-YYYY	or Applicant of Cited Document	or Relevant Figures Appear							
6-	W	US-6,156,303	12-05-2000	Russell et al	,						
P	X	US-5,622,856	04-22-1997	Natsoulis							

	FOREIGN PATENT DOCUMENTS												
		Foreign Patent Document			Pages, Columns,	76							
Examiner Initials*	caminer Cite Country Code ³ - Number ⁴ -Kind		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Unes, Where Relevant Passages or Relevant Figures Appear								
B	Y	PCT WO01/23597 A2	04-05-2001	G. Gao									
	Z	PCT WO01/23001 A2	04-05-2001	M. Croyle									
	AA	PCT WO01/83692 A2	11-08-2001	M. Hildinger									
R	BB	PCT WO01/40455 A2	06-07-2001	G. Gao									

Examiner Signature	Date Considered 117110
	The black is to an affecting the built with the party of the property of the party

* EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450.



PTO/SB/08B (08-00)

Approved for use through 4/30/2003.

OMB 0651-0031

U.S. Patent and Trademark Office;
U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are regulred to respond to a collection of information unless it valid OMB control number.

Substitut	e for forn	n 1449/PT(Complete if Known			
	TNE	ORMA	TION	Application Number	10/696,261		
		CLOS		Filing Date	October 29, 2003		
STATEMENT BY			NT BY	First Named Inventor	James M. Wilson		
		PLIC		Group Art Unit	1635		
(Use as π	nany shee	ts as necessary)	Examiner Name	Brian A. Whiteman		
Sheet	4	of	8	Attorney Docket Number	GNV31CUSA/ UPN-K1774DIV2		

Examiner Initials*	Cite No.¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), columeousse number(s), publisher, city and/or country where published					
Recombinant AAV Vectors, Molecular Therapy, Vol. 7, No. pp. 419-425, (March 2003) DD RABINOWITZ ET AL, Cross-Packaging of a Single Adeno Associated Virus (AAV) Type 2 Vector Genome into Multip AAV Serotypes Enables Transduction with Broad Specificit Journal of Virology, Vol. 76, No. 2, pp. 791-801, (January 2 HAUCK ET AL, Characterization of Tissue Tropism Determ of Adeno-Associated Virus Type 1, Journal of Virology, Vol. 76, No. 2, pp. 791-801, (January 2 HAUCK ET AL, Characterization of Tissue Tropism Determ of Adeno-Associated Virus Type 1, Journal of Virology, Vol. 76, No. 2, pp. 791-801, (January 2 HAUCK ET AL, Characterization of Tissue Tropism Determ of Adeno-Associated Virus Type 1, Journal of Virology, Vol. 76, No. 2, pp. 791-801, (January 2 HAUCK ET AL, Characterization of Tissue Tropism Determ of Adeno-Associated Virus Type 1, Journal of Virology, Vol. 76, No. 2, pp. 791-801, (January 2 HAUCK ET AL, Characterization of Tissue Tropism Determ of Adeno-Associated Virus Type 1, Journal of Virology, Vol. 76, No. 2, pp. 791-801, (January 2 HAUCK ET AL, Characterization of Tissue Tropism Determ of Adeno-Associated Virus Type 1, Journal of Virology, Vol. 76, No. 2, pp. 791-801, (January 2 HAUCK ET AL, Characterization of Tissue Tropism Determ of Adeno-Associated Virus Type 1, Journal of Virology, Vol. 76, No. 20, pp. 791-801, (January 2 HAUCK ET AL, Characterization of Tissue Tropism Determ of Adeno-Associated Virus Type 1, Journal of Virology, Vol. 76, No. 20, pp. 791-801, (January 2 HAUCK ET AL, Characterization Of Tissue Tropism Determ of Adeno-Associated Virus Type 1, Journal of Virology, Vol. 76, No. 20, pp. 791-801, (January 2 HAUCK ET AL, Characterization Of Tissue Tropism Determ of Adeno-Associated Virus Type 1, Journal of Virology, Vol. 76, No. 20, pp. 791-801, (January 2 HAUCK ET AL, Characterization Of Tissue Tropism Determ		HAUCK ET AL, Generation and Characterization of Chimeric Recombinant AAV Vectors, Molecular Therapy, Vol. 7, No. 3, pp. 419-425, (March 2003)					
		RABINOWITZ ET AL, Cross-Packaging of a Single Adeno- Associated Virus (AAV) Type 2 Vector Genome into Multiple AAV Serotypes Enables Transduction with Broad Specificity, Journal of Virology, Vol. 76, No. 2, pp. 791-801, (January 2002)					
		HAUCK ET AL, Characterization of Tissue Tropism Determinants of Adeno-Associated Virus Type 1, Journal of Virology, Vol. 77, No. 4, pp. 2768-2774, (February 2003)					
	FF	ARRUDA ET AL, Safety and Efficacy of Factor IX Gene Transfer to Skeletal Muscle in Murine and Canine Hemophilia B Models by Adeno-Associated Viral Vector Serotype 1, Blood First Edition Paper, (September 11, 2003)					
ρ— GG		E. RUTLEDGE ET AL, Infectious Clones and Vectors Derived from Adeno-Associated Virus (AAV) Serotypes Other Than AAV Type 2, Journal of Virology, 72(1):309-319 (January, 1998)					

Examiner Signature		1	L	k		Date Considere	:đ	1	ſ)	0	10	1	
* EXAMINER:	Initi	al if ref	eŕer	ce	considered, whether or not citation	is in conf	ormance	witt	ı M	1PE	Pé	509.	Draw line	
through citation	if no	t in con	forn	nar	ce and not considered. Include co	py of this	form with	nex	ĸt (con	nm	unic	ation to	
applicant. 1 App	lican	t's unio	ue d	ita	ion designation number (optional)	. ² Applica	nt is to pi	ace	a	che	ck	mar	k here If Er	alish

applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450.



Approved for use through 4/30/2003.

OMB 0651-0031

U.S. Patent and Trademark Office;

U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it valid OMB control number.

Substitute for form 1449/PTO				Complete if Known			
	TNE	TEMA	TION	Application Number	10/696,282		
INFORMATION DISCLOSURE				Filing Date	October 29, 2003		
STATEMENT BY				First Named Inventor	James M. Wilson		
		PLIC		Group Art Unit	1635		
(Use as m	any shee	ets as necessary)	Examiner Name	Brian A. Whiteman		
Sheet	5	of	8	Attorney Docket Number	GNV31CUSA/ UPN-K1774DIV2		

		OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS					
Examiner Cite Initials* No.1		Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), columeousse number(s), publisher, city and/or country where published	T²				
P~ HH		W. XIAO ET AL, Gene Therapy Vecotrs Based on Adeno- Associated Virus Type 1, Journal of Virology, 73(5):3994-4003 (May, 1999)					
	II	H. CHAO ET AL, Several Log Increase in Therapeutic Transgene Delivery by Distinct Adeno-Associated Viral Serotype Vectors, Molecular Therapy, 2(6):619-623 (December 2000)					
	IJ	R. KOTIN ET AL, Site-Specific Integration by Adeno-Associated Virus, Proc. Natl. Acad. Sci. USA, 87:2211-2215 (March, 1990)					
	KK	K. FISHER ET AL, Recombinant Adeno-Associated Virus for Muscle Directed Gene Therapy, Nature Medicine, 3(3):306-312 (March, 1997)					
by IT		X. XIAO ET AL, Efficient Long-Term Gene Transfer into Muscle Tissue of Immunocompetent Mice by Adeno-Associataed Virus Vector, Journal of Virology, 70(11):8098-8108 (November, 1996)					

Examiner Signature	Dri. Ma	Date Considered	
* EXAMINER: through citation applicant. ¹ Applicant of Applicant of Applicant of Applicant of Examination of Confidentiality is including gather upon the individual of Applicant of Confidential of Confide	: Initial if reference considered, whether if not in conformance and not considered plicant's unique citation designation number is attached. This collection of information or retain a benefit by the public which is governed by 35 USC 122 and 37 CFR 17 ring, preparing, and submitting the computation on the amount orden, should be sent to the Chief Information.	or not citation is in conformance with MPEP 609. Draw line ed. Include copy of this form with next communication to ther (optional). Applicant is to place a check mark here if Englimation is required by 37 CFR 1.97 and 1.98. The information is its file (and by the USPTO to process) an application. 1.14. this collection is estimated to take 2 hours to complete, pleted application form to the USPTO. Time will vary depending that of time you require to complete this form and/or suggestions mation Officer, U.S. Patent and Trademark Office, U.S. NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.	5 I



Approved for use through 4/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

> Complete if Known 10/696,261

October 29, 2003

INFORMATION

Substitute for form 1449/PTO

DISCLOSURE STATEMENT BY			URE	Filing Date	October 29, 2003	
				First Named Inventor	James M. Wilson	
APPLICANT (Use as many sheets as necessary)				Group Art Unit	1635	
				Examiner Name	Brian A. Whiteman	
6 1	_	-6	0	Attorney Docket	GNV31CUSA/	
Sheet	6 of 8		Ø	Number	UPN-K1774DIV2	

Application Number

Examiner Cite No.1		Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), columeousse number(s), publisher, city and/or country where published					
BL MM		R. SNYDER ET AL, Persistent and Therapeutic Concentrations of Human Factor IX in Mice After Hepatic Gene Transfer of Reocmbinant AAV Vectors, Nature Genetics, 16:270-276 (July, 1997)					
	NN	N. MUZYCZKA, Use of Adeno-Assicated Virus as a General Transduction Vector for Mamalian Cells, Current Topics in Microbiology and Immunology, 158:97-129, (1992)					
	00	R. SAMULSKI ET AL, Targeted Integration of Adeno-Associated Virus (AAV) into Human Chromosome 19, EMBO Journal, 10(12):3941-3950 (December, 1991)					
	PP	K. BERNS, Parvoviridae: The Viruses and Their Republication, in B. N. Fields et al, Fields Virology, 3 rd ed., Vol. 2, Chapter 69, pp. 2173-2197 (Lippincott-Raven Publishers, Philadelphia, PA) (1996)	i				
QQ R. SNYDER ET AL, Features of the Adeno-Associated Virus Origin Involved in Substrate Recognition by the Viral Rep Prote Journal of Virology, 67(10):6096-6104 (October, 1993)							
RR K. BERNS, Parvovirus Replication, Microbiological Reviews, 54(3):316-329 (September, 1990)							

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application.

Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, Alexandria VA 22313-1450



Approved for use through 4/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office;

U.S. DEPARTMENT OF COMMERCE
U.S. DEPARTMENT OF COMMERCE
U.S. DEPARTMENT OF COMMERCE
U.S. DEPARTMENT OF COMMERCE
U.S. DEPARTMENT OF COMMERCE contains a valid OMB control number.

Complete If Known

INFORMATION
DISCLOSURE
STATEMENT BY
ADDITCANT

Substitute for form 1449/PTO

Sheet

(Use

INFO	TRMA	TTON	Application Number	10/696,261
INFORMATION DISCLOSURE			Filing Date	October 29, 2003
STATEMENT BY APPLICANT se as many sheets as necessary)			First Named Inventor	James M. Wilson
			Group Art Unit	1635
		ts as necessary)	Examiner Name	Brian A. Whiteman
7	of	8	Attorney Docket Number	GNV31CUSA/ UPN-K1774DIV2

		OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), columeousse number(s), publisher, city and/or country where published	T²
bh	SS	R. SAMULSKI ET AL, Cloning of Adeno-Associated Virus into pBR322: Rescue of Intact Virus from the Recombinant Plasmid in Human Cells, Proc. Natl. Acad. Sci. USA, 79:2077-2081 (March, 1982)	
	TT	J. CHIORINI ET AL, Cloning of Adeno-Associated Virus Type 4 (AAV4) and Generation of Recombinant AAV4 Particles, Journal of Virology, 71(9):6823-6833 (September, 1997)	
	UU	S. MURAMATSU ET AL, Nucleotide Sequencing and Generation of an Infectious Clone of Adeno-Associated Virus 3, Virology, 221:208-217, (1996)	
	VV	C. BALAGUE ET AL, Adeno-Associated Virus Rep78 Protein and Terminal Repeats Enhance Integration of DNA Sequences into the Cellular Genome, Journal of Virolgoy, 71(4):3299-3306 (April, 1997)	
	ww	R. SUROSKY ET AL, Adeno-Associataed Virus Rep Proteins Target DNA Sequences to a Unique Locus in the Human Genome, Journal of Virology, 71(10):7951-7959 (October, 1997)	
k 1	XX	X. XIAO ET AL, Gene Transfer by Adeno-Associated Virus Vectors into the Central Nervous System, Experimental Neurology, 144:113-124 (1997)	

Exampler	Date	- 1 M /9	
Cyaninet Mi M	1 000	1 11 /70101	
Signature ASA.	Concidered	1 11(/ / 0 / 13)	
1 Signature 1 PT / I/A / I/L 4(1)	Congruered	1 10 1 / 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FÉES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450.



Approved for use through 4/30/2003. OM8 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office;
U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it
contains a valid OMB control number.

Substitu	ite for form 1449/PTO
	INFORMATION
	DISCLOSURE
	STATEMENT BY
	APPLICANT
	(Use as many sheets as necessary)

of

8

8

Sheet

Application Number 10/696,261

Filing Date October 29, 2003

First Named James M. Wilson

Group Art Unit 1635

Examiner Name Brian A. Whiteman

Attorney Docket GNV31CUSA/

UPN-K1774DIV2

			
Examiner Initials*	Cite No.1	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), columeousse number(s), publisher, city and/or country where published	T²
R	YY	ROSE ET AL, Microbiology, Vol. 546, Pages, 86-92, (1966)	
	ZZ	ANDERSON ET AL, Nature, Vol. 392, Pages, 25-30, (1998)	
	AAA	VERMA, Nature, Vol. 389, Pages 239-242, (1997)	
er	BBB	ORKIN ET AL, Report and Recommendations of the Panel to Assess the NIH Investments in Research on Gene Therapy, issue by the National Institute of Health, (December 7, 1995)	

Number

Examiner //)	Date M Dark
Signature 17 \(\Lambda \) \(\Lambda \)	Considered // // //

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450.

FEB 2 L 7004 W

PTO/SB/08B (08-00)
Approved for use through 4/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/696,261	
INFORMATION DISCLOSURE				Filing Date	October 29, 2003	
STATEMENT BY APPLICANT			APPLICANT	First Named Inventor	James M. Wilson, M.D., Ph.D.	
. ((Use as many sheets as necessary)			Group Art Unit	1635	
				Examiner Name	Brian A. Whiteman	
Sheet 1 of 1				Attorney Docket Number	GNV31CUSA/K1774DIV2	

			U.S. PATENT DOCUMENT	rs	
		Document Number		Name of	
Examiner Initials*	Cite No. ¹	Number-Kind Code ^{2(if} known)	Publication Date MM-DD-YYYY	Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
D~	CCC	US-2002-0159978 A1	10-31-2002	Allen	

			FOREIGN 1	PATENT DOCUMENTS		· · · · · · · · · · · · · · · · · · ·	
Examiner Initials*	Cite No. ¹	Foreign Patent Doc	ument	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where	T ⁶
		Country Code ³ - Number Code ⁵ (if known)	-Kind	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
							_
•							
			<u>.</u>				-

			· · · · · · · · · · · · · · · · · · ·	
Evaminer h	. 1	Date	1 .	
- LAGITURE 1	5 6	Date	11/9.	-4.3
Signature (1) A c	11	Considered	111 7 1	וחו
1 Signature 1 12 W	W/60	Considered	עט ווו	(U)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

document. ** Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST. 16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Approved for use through 4/30/2003.
OMB 0651-0031
U.S. Patent and Trademark Office;
U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it valid OMB control number.

Substitut	e for form	1449/PTC		Complete If Known		
	TNEC	DRMA'	TION	Application Number	10/696,261	
INFORMATION DISCLOSURE				Filing Date	October 29, 2003	
STATEMENT BY		First Named Inventor	James M. Wilson			
	APPLICANT			Group Art Unit	1635	
(Use as many sheets as necessary)		Examiner Name	Brian A. Whiteman			
Sheet	1	of	1	Attorney Docket Number	GNV31CUSA/ UPN-K1774DIV2	

Examiner Initials*	Cite No.1	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), columeousse number(s), publisher, city and/or country where published	T ²
R	DDD	SURACE ET AL, Delivery of Adeno-Associated Virus Vectors to the Fetal Retina: Impact of Viral Capsid Proteins on Retinal Neuronal Progenitor Transduction, Journal of Virology, Vol. 77, No. 14, pp. 7957-7963, (July 2003)	
			<u> </u>

Examiner Signature	Bn	1 Na			Date Considered		1201	נט	
* EXAMIN	ER: Initial If re	eference cons	idered, whether or	r not citation l	s in conform	ance wil	h MPEP	609. Draw Ilne	
through citat	tion if not in co	onformance a	nd not considered.	. Include copy	of this form	with ne	ext comm	nunication to	
applicant. 1	Applicant's uni	ique citation	designation number	er (optional). 3	Applicant is	to place	a check	mark here If E	nglish
language Tra	inslation is att	ached. This c	ollection of inform	ation is requir	ed by 37 CF	R 1.97 a	nd 1.98.	The Information	on is
required to o	btain or retain	a benefit by	the public which i	s to file (and l	by the USPTO) to pro	cess) an	application.	
C04		L. 35 HCC 4	22 27 OFR 4 4				-1 3 ha		_

Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (08-00)

Approved for use through 4/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
		Application Number	10/696,261		
INF	ORMA'	TION	DISCLOSURE	Filing Date	October 29, 2003
	STATEMENT BY APPLICANT (Use as many sheets as necessary)			First Named Inventor	James M. Wilson
(L				Group Art Unit	1635
				Examiner Name	Brian A. Whiteman
Sheet	1	of	1	Attorney Docket Number	GNV31CUSA/K1774DIV2

			U.S. PATENT DOCUMENT	S	
	l	Document Number		Name of	
Examiner Initials*	Cite No. ¹	Number-Kind Code ^{2(if} known)	Publication Date MM-DD-YYYY	Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

Initials* No.	Cite No.1	Country Code ³ - Number ⁴ -Kind			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited	Pages, Columns, Lines, Where Relevant Passages or Relevant	T
	EEE	PCT	(if known) WO 02/063025	A2	08-15-2002	Document Figures Avigen, Inc.	Figures Appear	-
								_

Examiner	b 11	Date	
Signature	1 mi Win	Considered \\(\lambda \lambda	
	1 7001	(1,0)03	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. If Mind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.